Coats Plus resource center
Research & Clinical Resources
Explore original studies and trusted references, understand their limits, and follow the questions researchers are still working to answer.
04 / Clinician reference
Recognize the pattern.
Interrogate the evidence.
A focused starting point for clinicians—not a consensus protocol, prescribing guide or replacement for specialist assessment.
Phenotype, imaging and differential diagnosis
Consider a multisystem disorder when retinal telangiectasia, exudation or peripheral avascularity occurs with neurological or systemic features. The classic neuroimaging pattern includes calcifications, cysts and leukoencephalopathy; the complete pattern may not be present at every assessment.
Review isolated Coats disease, SNORD118-associated LCC, other inherited retinal vascular disorders and other relevant neurogenetic conditions in the clinical context. Published adult cases show that age alone should not exclude consideration.
Molecular evaluation and interpretation
CTC1 and STN1 are established genes in the published Coats Plus literature. A rare homozygous POT1-associated family has also been described. Choose the testing approach with clinical genetics and the diagnostic laboratory, taking phenotype, variant classification and inheritance into account.
Review whether findings are biallelic and, when relevant, in trans. A VUS should not be treated as molecular confirmation. A telomere-length result is not a stand-alone test for this phenotype. Do not transfer risk estimates from a different POT1-associated disorder without variant-specific interpretation.
Management priorities and published treatment experience
Coordinate retinal, neurological, gastrointestinal/hepatic, hematological, skeletal and growth concerns according to the patient’s findings. Retinal interventions, treatment of bleeding and other complication-directed approaches appear in small reports.
Published bevacizumab and octreotide experiences are uncontrolled case evidence. The neurological bevacizumab report described improvement followed by further progression. They do not establish overall efficacy, optimal timing, dosing, duration or long-term safety in Coats Plus. Review the full paper and individual risks with the relevant specialists before considering any off-label intervention.
Infant retinal case · Bevacizumab report · GI bleeding report
Useful material for a referral or second opinion
- Clinical timeline, growth data and a three-generation family history where available.
- Original molecular report, transcript/variant nomenclature, classifications and parental testing results.
- Retinal photographs/angiography and brain imaging, with access to the actual images when appropriate.
- Relevant blood counts, GI/liver investigations, fractures, medication history and treatment response.
- The family’s priorities, current supports and a named coordinating clinician.
This is a practical documentation checklist, not a mandatory testing panel. Share records only through an appropriate clinical channel.
05 / Research & trusted reading
Follow the source.
Know the strength of the evidence.
Original studies, clinical reports and practical guides, collected in one searchable library. Begin with the overview or filter by the question you are trying to answer.
28 resources
Adult-onset disease and a new STN1 variant
Ozen et al. · Clinical Genetics 109:813–815
A report expands the published STN1 variant spectrum in adult-onset multisystem disease. The publicly available abstract is brief; the full article needs review before drawing patient-specific conclusions.
Abstract · full text may require access ↗Seeing the peripheral retina with OCT angiography
Chaaya et al. · Ophthalmic Surgery, Lasers & Imaging Retina 56:437–441
A 24-year-old initially diagnosed with familial exudative vitreoretinopathy was diagnosed with Coats Plus after genetic evaluation. Widefield imaging documented peripheral vascular changes. One case does not establish a universal screening protocol.
Abstract · full text may require access ↗Hidden genetic causes of unusual ROP
da Cruz et al. · American Journal of Ophthalmology 274:67-75
Of 19 babies whose retinopathy of prematurity looked unusual, 4 had a telomere disorder, 3 of them with CTC1 changes. Unusual ROP can be an early clue to Coats Plus. A small, selected group, so it doesn’t tell us how common this is.
Abstract ↗A nucleoside therapy trial for telomere disorders
Boston Children’s Hospital · ClinicalTrials.gov NCT06817590
A Phase 1 trial testing oral nucleosides (deoxycytidine and thymidine) in children and adults with telomere disorders. CTC1, STN1 and POT1 are among the eligible genes. A listing is not a guarantee of eligibility or benefit; confirm details with the study team.
View trial listing ↗Bevacizumab for eye swelling and gut bleeding
Khan et al. · Journal of VitreoRetinal Diseases
A girl first thought to have FEVR was found to have Coats Plus from STN1 changes. IV bevacizumab, given for gut bleeding, also cleared swelling in her retina. One patient’s experience, not proof the treatment works for others.
Abstract ↗Coats Plus can be diagnosed in adulthood
Kayarian et al. · Journal of VitreoRetinal Diseases 7:562–564
This report describes a 38-year-old with retinal vascular abnormalities and systemic findings. Genetic testing confirmed CTC1-associated disease. It illustrates variation in presentation, not a prediction of another person's course.
Free PDF · 3 pages ↗How CST protects the ends of chromosomes
Cai & de Lange · Genes & Development 37:555
A readable review of the CST complex (CTC1, STN1, TEN1) and how it finishes and protects chromosome ends, including what goes wrong in Coats Plus. Laboratory science, not treatment guidance.
Free full text ↗Retinal management in a premature infant
Sears et al. · Journal of VitreoRetinal Diseases 7:74–78
The authors describe retinal findings, genetic confirmation and a course involving laser and corticosteroids. Improvement in one infant cannot establish which treatment is safest or most effective for other patients.
Free full text ↗Bevacizumab and neurological symptoms
Sharayah et al. · Annals of Child Neurology 31:52–55
A single-patient report describes temporary neurological improvement during bevacizumab treatment, followed by further disease progression. This uncontrolled experience does not establish a cure, durable benefit or long-term safety. Full specialist review is essential.
Publisher article · PDF available ↗Recurrent gastrointestinal bleeding
Hoşnut, Şahin & Akçaboy · Turkish Journal of Pediatrics 64:166–170
The authors report control of recurrent bleeding with octreotide in a selected child. This adds to a small case literature; it does not establish a standard treatment regimen for all Coats Plus patients.
Free article & PDF ↗Recognizing the brain and body findings
Maia et al. · BMJ Case Reports 15:e249702
A clinical imaging report illustrates calcifications, cysts and white-matter changes alongside findings outside the brain. Helpful for recognizing the syndrome and distinguishing related diagnoses; a case report is not a prevalence study.
Free full text ↗Coats Plus in two brothers, first mistaken for ROP
Lopez-Canizares et al. · Ophthalmic Genetics 43(4)
Two brothers with Coats Plus. The younger was first thought to have atypical ROP and was diagnosed only after his older brother had a seizure and tremor at age 4. Laser and bevacizumab improved the retinas. This is the Docobo family’s case.
Abstract ↗Severe gut bleeding in a child with Coats Plus
Bozkurt et al. · BMC Pediatrics
A 6-year-old with bleeding blood vessels in the stomach and intestines. Octreotide helped at first, but the bleeding became fatal. Shows why gut bleeding in Coats Plus is an emergency.
Free full text ↗Gastrointestinal hemorrhage across telomere disorders
Himes et al. · Journal of Pediatrics 230:55–61.e4
This 16-patient, 11-center series included several telomere biology disorders, including Coats Plus. It describes GI bleeding, interventions and outcomes. Mixed diagnoses and retrospective data limit what it can establish for Coats Plus specifically.
Abstract · mixed-condition evidence ↗Additional STN1 variants
Acharya et al. · Molecular Genetics & Genomic Medicine 9:e1708
A report of compound heterozygous STN1 variants broadens the genetic literature. Individual variants require clinical laboratory interpretation and family evaluation; a gene name alone does not confirm a diagnosis.
Abstract & free full-text link ↗Managing telomere disorders, including Coats Plus
Niewisch & Savage · Expert Review of Hematology 12(12):1037-1052
A National Cancer Institute review placing Coats Plus within the telomere disorders, with care and monitoring guidance. Covers the whole group, so not every point applies to Coats Plus.
Free full text ↗STN1 joins the Coats Plus gene spectrum
Simon et al. · Journal of Experimental Medicine 213:1429–1440
Two affected individuals with STN1 variants, together with laboratory studies, connected STN1 to Coats Plus and defects in telomere and genome maintenance. This is mechanistic evidence, not a treatment trial.
Free full text ↗A rare POT1-associated Coats Plus phenotype
Takai et al. · Genes & Development
A homozygous POT1 variant was identified in two affected siblings. Cell experiments investigated telomere maintenance. These findings should not be generalized to every POT1 variant or confused with dominant POT1 tumor predisposition.
Free full text ↗Why Labrune syndrome is a different diagnosis
Jenkinson et al. · Nature Genetics 48:1185–1192
Biallelic SNORD118 variants were linked to leukoencephalopathy with calcifications and cysts (Labrune syndrome). Similar brain imaging does not make Labrune syndrome and Coats Plus interchangeable.
Free full text · related condition ↗Why Labrune syndrome is separate from Coats Plus
Livingston et al. · Neuropediatrics 45(3):175-182
Labrune patients had no CTC1 changes and no disease outside the brain, showing it is a different disorder even though brain scans look alike. Pairs with the SNORD118 card already in the library.
Abstract ↗Identifying CTC1 in multisystem disease
Polvi et al. · American Journal of Human Genetics 90:540–549
This foundational study identified recessively inherited CTC1 variants in people with cerebroretinal microangiopathy and systemic features. It helped establish a molecular explanation for Coats Plus.
Free full text ↗A plain-language introduction
MedlinePlus Genetics · Coats Plus syndrome
An accessible introduction to symptoms, inheritance and CTC1. This older overview is a useful starting point; read the newer gene-specific papers alongside it.
Free patient overview ↗Information and help finding resources
Genetic and Rare Diseases Information Center
A disease overview and a route to GARD information specialists. GARD helps people navigate rare-disease information; it does not replace a treating medical team.
Free patient resource ↗Telomere biology disorder guidelines
Team Telomere · Second edition
A broad reference with chapters on diagnosis, genetic counseling, organ complications and daily life. Many chapters concern other telomere disorders: a clinician must decide what applies to Coats Plus.
Free full guide & chapter PDFs ↗Understanding an uncertain genetic result
NHGRI · Variant of uncertain significance
A short explanation of a VUS: a genetic change whose relationship to disease remains unclear. Bring the original laboratory report to a genetics professional for interpretation.
Free glossary ↗Explore voluntary research participation
Coordination of Rare Diseases at Sanford (CoRDS)
An international rare-disease registry, including people awaiting a diagnosis. Participation and data-sharing choices are explained by Sanford. A registry is not a treatment trial and does not guarantee a research opportunity.
Free registry information ↗Small-vessel damage at the heart of Coats Plus
Briggs et al. · American Journal of Medical Genetics A 146A(2):182-190
Showed that Coats Plus and CRMCC are the same disease and proposed that damage to the body’s smallest blood vessels drives it. Written before the genes were found.
Abstract ↗The paper that named Coats Plus
Crow et al. · Neuropediatrics 35(1):10-19
Named “Coats plus” and described how it affects the eyes, brain, bones and other organs over time. A historical foundation, written before genetic testing was available.
Abstract ↗No matching resources. Try a broader term or reset the search.
This is a curated starting library, not a systematic review or a claim to include every publication. Publication dates are shown separately from this page’s review date. Linking to a source does not imply its authors endorse the foundation.
06 / Research notes & updates
Progress, with perspective.
Brief reading notes on published work. These are research summaries, not new treatment announcements.
The STN1 story continues to expand.
Ozen and colleagues report an additional biallelic STN1 variant associated with adult-onset multisystem disease. It adds to the genetic literature; the short public abstract does not provide a basis for new care recommendations. Published online December 2025.
Read the source and limits →A closer view of the peripheral retina.
A single-patient report highlights widefield OCT angiography in a person whose presentation resembled FEVR. Its practical message is diagnostic awareness and careful interpretation, not a new cure.
Read the imaging report →Adult presentations matter.
A report of diagnosis at age 38 illustrates why symptoms, records and genetic results need to be considered together. A published case can broaden awareness while still telling us very little about population-wide outcomes.
Open the free case-report PDF →07 / Taking part in research
Turn interest into informed questions.
Explore trial listings.
Search ClinicalTrials.gov for Coats Plus and related gene terms. Read the actual condition, eligibility criteria, recruitment status and study location. A listing is not government approval, a guarantee of benefit or confirmation that a patient is eligible.
Before considering a study, ask about its purpose, visits, costs, travel, risks, data use and the right to withdraw. Confirm details with the study team and your treating clinician.
Search ClinicalTrials.gov ↗Learn about CoRDS.
Sanford Research’s Coordination of Rare Diseases at Sanford is a broad rare-disease registry. It includes people with a rare diagnosis and people still seeking one. Review consent and data-sharing options directly with Sanford.
A registry collects information and may help connect people with research opportunities. It is different from receiving an experimental treatment. This link does not imply a foundation partnership.
Read the CoRDS participation FAQ ↗No specific trial is being advertised here as open or suitable for Coats Plus. Recruitment and eligibility change; verify them at the source.
12 / Save, print & share
Useful resources to take with you.
Real downloads and original sources. Publisher PDFs remain on their owners’ websites so you can see the publication and context.
Where would you like to go next?
Understanding Coats Plus
The condition, genes, affected body systems, and common questions explained.
Open the guide →RESOURCE GUIDECommunity & Get Involved
Meet the families, find community, and offer your knowledge, connections, or support.
Open the guide →Editorial status: Educational draft for foundation and independent clinical review. This information is not a diagnosis or an individual treatment plan. Sources, medical copy, external links and community details still require review before public launch.
Back to the top ↑